Teva Pharmaceuticals?A Market Leader
Adding diversity and depth to its product line, pipeline, and geographic markets.
In the generic pharmaceutical market, Teva Pharmaceuticals (North Wales, PA) is the leader without peer, ranking number one in prescriptions filled, sales dollars, Abbreviated New Drug Application (ANDA) filings including first-to-files, product launches, breadth of product line, vertical integration, pedigree technology, and many other criteria.
Teva now has more than 28,000 employees and annual sales that totaled $9.4 billion in 2007. Over the last few years, Teva has added diversity and depth to its product line, pipeline, and geographic markets; expanded its reach in the primary distribution channels; and added new product specialties.
Teva Health Systems (THS), the division of Teva focused on institutional segments, is quickly building a dominant position of its own. By structuring a sales approach that leverages everything Teva has in its vast existing portfolio of oral and injectable formulations, together with the most productive product pipeline in the industry, THS has established itself as a major player in the market.
Today, Teva offers generic pharmaceutical products in a wider variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables, inhalants, unit-dose, and biopharmaceuticals. Teva products are used in a number of different therapeutic categories, including cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, antidiabetic, analgesic, dermatology, and respiratory.
Teva has a well-established and balanced portfolio of products that customers want, and a strong active pharmaceutical ingredient business to meet their needs. In addition, a vertically integrated structure ensures that as the company continues to grow, Teva can maintain its high standard of quality and its longstanding commitment to customer satisfaction. With more than 300 products and 1000 SKUs, Teva is able to respond to the wide range of needs of patients, customers, and health care providers, both therapeutically and economically.
Teva launched numerous new products in 2007 and has 150 ANDAs pending FDA approval as of June 30, 2008. Recently launched products include Lamotrigine Tablets, AB-rated to GlaxoSmithKline's Lamictal; Risperidone Tablets USP, AB-rated to Janssen's Risperdal; Budeprion XL 150 mg, AB-rated to GlaxoSmithKline's Wellbutrin XL; Alendronate Sodium Tablets, AB-rated to Merck's Fosamax; Zaleplon Capsules, AB-rated to King's Sonata; Cetirizine HCl Syrup, AA-rated to Pfizer's Zyrtec; Selfemra (Fluoxetine) Capsules, AB-rated to Eli Lilly's Sarafem; and Ropinirole HCl Tablets, AB-rated to GlaxoSmithKline's Requip. Recent THS launches include Epoprostenol Sodium for Injection, AP-rated to GlaxoSmithKline's Flolan; Ciprofloxacin Injection and Tablets, AP/AB-rated to Bayer's Cipro; Irinotecan HCl Injection, AP-rated to Pfizer's Camptosar; and Granisetron HCl Injection and Tablets, AP/ABrated to Roche's Kytril.
Marketed by Teva Pharmaceuticals (North Wales, PA)
Alendronate Sodium Tablets
AB-rated and bioequivalent to Merck's Fosamax Tablets
Available in strengths of 5, 10, 35, 40, and 70 mg, in various bottle sizes including
Ropinirole Hydrochloride Tablets
AB-rated and bioequivalent to GlaxoSmithKline's Requip Tablets
Available in strengths of 0.25, 0.5, 1, 2, 3, 4, and 5 mg, in bottles of 100
Teva is the leading provider of affordable generic medicines. The company's robust pipeline of future productsis a source of continuing value to American consumers.
Teva Pharmaceuticals can be reached by mail at 1090 Horsham Road, PO Box 1090, North Wales, PA 19454-1090, by phone at 888-TEVA-USA (888-838-2872), by e-mail at
, and on the Web at www.tevausa.com.